E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces First Quarter 2023 Financial Results
May 03, 2023 16:01 ET | electroCore, Inc.
Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Annual Aegis Virtual Conference
May 01, 2023 16:01 ET | electroCore, Inc.
ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
April 24, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
April 12, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
April 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
April 04, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:05 ET | electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
National Headache Fo
National Headache Foundation Makes WorkMigraine Program Resources Free to the Public
January 05, 2023 15:18 ET | National Headache Foundation
Chicago, Illinois, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) announced it is now making available free to the public its proven WorkMigraine program to help employers...
Axsome Logo.png
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022 07:28 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...